Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo
BMC Cancer
.
2023 Jul 7;23(1):636.
doi: 10.1186/s12885-023-11135-3.
Authors
Yu-Yin Xu
#
1
2
,
Li Chen
#
3
,
Gui-Lan Wang
1
,
Jia-Ming Zhou
1
,
Yi-Xin Zhang
4
,
Yin-Ze Wei
4
,
Yuan-Yuan Zhu
5
,
Jing Qin
1
Affiliations
1
Department of Pathological Anatomy, Nantong University, Nantong, China.
2
Department of Nephrology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
3
Department of Pathological Anatomy, Nantong University, Nantong, China. bl1@ntu.edu.cn.
4
Department of Pathology, Affiliated Tumor Hospital, Nantong University, Nantong, China.
5
Biomics (Nantong) Co., Ltd, Nantong, China.
#
Contributed equally.
PMID:
37420163
PMCID:
PMC10326930
DOI:
10.1186/s12885-023-11135-3
No abstract available
Publication types
Retraction of Publication